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ABSTRACT
Organic cation transporters (OCTs) are members of the solute
carrier 22 family of transporter proteins that are involved in
absorption, distribution, and excretion of organic cations. OCT3
is localized in the apical (AP) membrane of enterocytes, but the
literature is ambiguous about OCT1 (mOct1) localization, with
some evidence suggesting a basolateral (BL) localization in
human and mouse enterocytes. This is contrary to our pre-
liminary findings showing AP localization of OCT1 in Caco-2 cell
monolayers, an established model of human intestinal epithelium.
Therefore, this study aims at determining the localization of OCT1
(mOct1) in Caco-2 cells, and human and mouse enterocytes.
Functional studies using OCT1-specific substrate pentamidine
showed transporter-mediated AP but not BL uptake in Caco-2
cells and human and mouse intestinal tissues. OCT1 inhibition
decreased AP uptake of pentamidine by ∼50% in all three sys-
tems with no effect on BL uptake. A short hairpin RNA-mediated
OCT1 knockdown in Caco-2 cells decreased AP uptake of pent-
amidine by ∼50% but did not alter BL uptake. Immunostaining
and confocal microscopy in all three systems confirmed AP
localization of OCT1 (mOct1). Our studies unequivocally show AP
membrane localization of OCT1 (mOct1) in Caco-2 cells and
human and mouse intestine. These results are highly significant
as they will require reinterpretation of previous drug disposition
and drug-drug interaction studies where conclusions were drawn
assuming BL localization of OCT1 in enterocytes. Most impor-
tantly, these results will require revision of the regulatory guidance
for industry in the United States and elsewhere because it has
stated that OCT1 is basolaterally localized in enterocytes.
Introduction
The intestine plays a critical role in the absorption of
nutrients and drugs. The intestinal epithelial cells (enter-
ocytes) are polarized by the presence of tight junctions, and
form a monolayer with the apical (AP) membrane facing the
luminal side and the basolateral (BL) membrane facing the
serosal side. Intestinal epithelium is the major barrier in the in-
testine and controls the absorption of nutrients and drugs.
Lipophilic compounds can cross this barrier by passive
diffusion across AP and BL membranes of epithelial cells.
However, hydrophilic and charged compounds can cross the
epithelial barrier either via a paracellular route, which is
highly inefficient, or transcellularly with the assistance of
one or more transporters that are present in epithelial cell
membranes.
Epithelial cells in the intestine, liver, and kidney have
specific transporters localized in either AP or BL membrane
to facilitate directional transport of compounds and ensure
their absorption by the intestine and excretion by the kidney
and/or liver. Organic cation transporters (OCTs) belong to the
solute carrier family 22 of polyspecific transporter proteins that
are expressed in the liver, kidney, intestine, and other organs,
transporting organic cationic compounds such as nutrients,
endogenous amines, and many cationic drugs. OCTs are
expressed as three different isoforms, namely, OCT1, OCT2,
and OCT3, and exhibit organ-specific distribution.
Like other transporters, OCTs are expressed in specific cell
membranes in epithelial tissues. For example, it is well es-
tablished that OCTs such as OCT1 and OCT3 are localized in
the sinusoidal (BL) membrane of human hepatocytes and are
responsible for the uptake of cations from blood into the
hepatocytes (Faber et al., 2003; Nies et al., 2009; Chen et al.,
2010); similarly, in the kidney OCT2 is localized in the BL
membrane of human renal proximal tubules and is responsible
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for the uptake of cations from the blood (Okuda et al., 1996;
Karbach et al., 2000; Motohashi et al., 2002). In the intestine,
OCT3 is expressed in the AP membrane of enterocytes and
mediates the uptake of cations from the lumen into the
enterocytes (Muller et al., 2005; Koepsell et al., 2007).
However, OCT1, which belongs to the same family of trans-
porters as OCT3, has been reported to be localized in the BL
membrane (Jonker et al., 2001; Wang et al., 2002; Watanabe
et al., 2002a,b; Muller et al., 2005; Koepsell et al., 2007;
Giacomini et al., 2010). This is surprising considering that
other members of the OCT family, when expressed in the
intestinal epithelium, are expressed in the AP membrane. It
can be argued that OCT1 is expressed in the BL membrane to
take up circulating organic cations into enterocytes; however,
the affinities of OCTs for most substrates are low [e.g.,
apparent Michaelis-Menten constant (Km) values . 500 mM]
(Koepsell et al., 2007) and hence a very high expression of the
transporter would be needed to play a role in the serosal
uptake and intestinal excretion of circulating organic cations.
Previous functional studies in our laboratory have sug-
gested that OCT1 is not localized in the BL membrane of
Caco-2 cell monolayers. The organic cation drug ranitidine,
which is a substrate for OCTs, showed saturable AP uptake
into Caco-2 cell monolayers with egress across the BL mem-
brane via passive diffusion processes (Bourdet et al., 2005;
Bourdet et al., 2006). BL uptake of ranitidine was mediated by
a transporter with a very high apparent Km value of 67 mM
(Lee et al., 2002); this kinetic behavior is not consistent with
the presence of OCT1 in the BL membrane of Caco-2 cell
monolayers. Another organic cation drug metformin, also
a substrate for OCTs (Kimura et al., 2005), showed saturable
AP uptake and nonsaturable inefficient BL uptake into Caco-2
cell monolayers (Proctor et al., 2008).
These data suggest, but do not provide definitive evidence
that OCT1 is apically localized in Caco-2 cell monolayers;
however, the results seem to rule out BL localization of the
transporter in this cell model. Preliminary immunolocaliza-
tion studies in Caco-2 cell monolayers suggested that OCT1
was localized in the AP membrane (Supplemental Fig. 1;
associated Supplemental Materials and Methods) (Ng, 2002).
In this study, we investigated the cellular localization of
OCT1 in Caco-2 cell monolayers as well as in mouse and
human intestinal epithelia so as to resolve the contradiction
between the ambiguous reports in the literature that suggest
BL localization of this transporter and the preliminary
findings in our laboratory that suggest AP localization of
OCT1 in Caco-2 cell monolayers.
Materials and Methods
Materials
Minimum essential medium with Eagle’s salts and L-glutamate,
HEPES (1M), penicillin-streptomycin-amphotericin B solution (100),
nonessential amino acids (100), geneticin, SuperScript III First-
Strand Synthesis SuperMix, TaqMan Gene Expression Master Mix,
and TaqMan Gene Expression Assays for OCT1 were obtained from
Life Technologies Corporation (Grand Island, NY). Restore Western
Blot Stripping Buffer and SuperSignal West Dura Extended Duration
Substrate Kit were purchased from Thermo Scientific (Rockford, IL).
Rabbit anti-human OCT1 antibody was purchased from Sigma-
Aldrich (cat. no. AV41516; St. Louis, MO). Alexa Fluor 568 goat
anti-rabbit IgG (A11036), Alexa Fluor 488 donkey anti-goat IgG
(A11055), normal goat serum (NGS), nitrocellulose membrane filter
paper sandwich, Nupage Western blot buffers, Bis-Tris gels, and
other Western blotting reagents were purchased from Invitrogen
(Carlsbad, CA). Radioimmunoprecipitation assay lysis buffer system,
rabbit anti-human P-glycoprotein (P-gp) antibody (sc-8313), rabbit
anti-human Na1/K1 ATPase antibody (sc-28800), goat anti-human
villin antibody (sc-7672), goat anti-rabbit IgG-CFL488 (sc-362262),
and goat anti-rabbit IgG-horseradish peroxidase (sc-2004) were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Human
and mouse jejunum paraffin sections were purchased from Zyagen
(San Diego, CA). Vectashield mounting medium with DAPI (49,6-
diamidino-2-phenylindole) was purchased from Vector Laboratories
(Burlingame, CA). [3H]Pentamidine (4,49-[pentane-1,5-diylbis(oxy)]diben-
zenecarboximidamide) was purchased from Moravek Biochemicals
and Radiochemicals (Brea, CA), and [14C]TEA was purchased from
American Radiolabeled Chemical Inc. (St. Louis, MO). Mitoxan-
trone (1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]-
anthracene-9,10-dione), desipramine (3-(10,11-dihydro-5H-dibenzo[b,
f]azepin-5-yl)-N-methylpropan-1-amine), and quinidine ((S)-(6-
methoxyquinolin-4-yl)((2R,4S,8R)-8-vinylquinuclidin-2-yl)methanol)
were purchased from Sigma-Aldrich. The Caco-2 (HTB-37) cell line
was obtained from the American Type Culture Collection (Manassas,
VA).
Caco-2 Cell Culture
Caco-2 cells were cultured as described previously elsewhere
(Proctor et al., 2008). Briefly, the cells (passage numbers 30–40) were
seeded at a density of 60,000 cells/cm2 on polycarbonatemembranes of
Transwells. The culture medium was changed the day after seeding
and every other day thereafter. Cell monolayers with transepithelial
electrical resistance greater than 300 V·cm2 were used for experi-
mentation at 21–28 days after seeding.
Generation of OCT1-Knockdown Caco-2 Clones
Three OCT1-specific small interfering RNA sequences (Sigma-
Aldrich) were evaluated for their ability to silence OCT1 gene
expression. Sequence 1 (sense strand: 59-GCUAUGAAGUGGACUG-
GAA-39; antisense strand: 59-UUCCAGUCCACUUCAUAGC-39) and
sequence 3 (sense strand: 59-CCAUCUGUGUGGGCAUCGU-39; anti-
sense strand: 59-ACGAUGCCCACACAGAUGG-39) had the highest
gene silencing activity (unpublished data). The antisense and sense
oligonucleotides were linked with a hairpin loop and annealed with
the respective complementary DNA oligonucleotides. Each resulting
double-stranded DNA was inserted into BamHI and HindIII sites of
the pRNATin-H1.2/Hygro vector (GenScript, Piscataway, NJ) to
generate a short hairpin RNA (shRNA) plasmid. Caco-2 cells at 90%
confluency were transfected with the shRNA plasmid, using the
Nucleofector System (Amaxa, Gaithersburg, MD) according to the
manufacturer’s protocol. Transfectants were selected by treatment
with 0.2 mg/ml hygromycin B for 3 weeks, and were screened by
quantitative real-time polymerase chain reaction (qRT-PCR) for OCT1
expression. Three clones (sequence 1 clone 43, and sequence 3 clones 21
and 27; i.e., 1-43, 3-21, 3-27) with the lowest gene expression, and
normalmorphology and growth rate were chosen for functional studies.
qRT-PCR for OCT1 Gene Expression in Caco-2 Cells
The mRNA expression of human OCT1 relative to 18s rRNA (18s)
was determined by qRT-PCR analysis. The qRT-PCR experiments
were conducted using established methods (Holmes et al., 2006) with
minor deviations. Total RNA was isolated from Caco-2 cell mono-
layers using an RNeasy Plus Mini Kit (Qiagen, Valencia, CA). We
synthesized cDNA from the total RNA (5 mg) using Superscript III
reverse transcriptase. An equal amount of RNA was included in a no-
reverse transcriptase control for each separate RNA sample. We
performed qRT-PCR using 1:20 dilutions of the cDNA. The PCR
reactions (45 cycles) were conducted using TaqMan Gene Expression
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Assays in an Applied Biosystems 7500 Real-Time PCR System
(Applied Biosystems, Foster City, CA). The expression of the 18s
housekeeping gene was determined in each RT-PCR experiment and
served as the normalization control (n 5 1).
Functional Uptake Studies
In Caco-2 cell monolayers, the initial AP and BL uptake of [14C]TEA
and [3H]pentamidine was quantified using methods outlined pre-
viously elsewhere (Proctor et al., 2008) with minor deviations. Uptake
of [14C]TEA (5 mM, 0.05 mCi/ml, 10 minutes) across the AP and BL
membranes was measured in the absence or presence of 500 mM
unlabeled TEA or 500 mM quinidine. [3H]Pentamidine (0.1 mM,
0.05 mCi/ml, 5 minutes) uptake was performed in control and OCT1-
knockdown cells. Mitoxantrone (25 mM) was used as the OCT1-
specific inhibitor (Koepsell et al., 2007; Han et al., 2012), and 500 mM
quinidine was used as the OCT pan inhibitor.
Human intestinal tissues collected from gastric bypass surgical
patients were procured from the University of North Carolina
Hospitals (Chapel Hill, NC), and all investigational experiments
were performed in accordance with approval from the institutional
review board at the Office of Human Research Ethics at the Uni-
versity of North Carolina at Chapel Hill and in compliance with federal
regulations. The tissues were stripped of the exterior seromuscula-
ture and serosa layers by sharp resection, and the intestinal epithe-
lium was mounted between two halves of a diffusion chamber insert.
The entire procedure was completed within 1 hour from collection so
as to preserve viability of the tissues.
The inserts were placed between two side-by-side diffusion cham-
bers. Krebs’ bicarbonate–Ringer’s buffer (KBR; 3 ml) at 37°C was
added to the AP and BL chambers and bubbled with oxygen/carbon
dioxide (95:5) gas to maintain tissue viability (Johnson et al., 2002).
For AP uptake studies, three intestinal epithelial samples were
preincubated for 30minutes at 37°Cwith 3ml of KBR buffer in the AP
and BL compartments.
After equilibration, the transepithelial electrical resistance was
measured (greater than 250 V×cm2) to ensure the epithelial integrity
of the intestinal tissue. KBR buffer from the BL chamber was removed
and replaced with fresh buffer; buffer in the AP chamber was replaced
with [3H]pentamidine [0.1mM, 0.05mCi/ml] in KBR, or [3H]pentamidine
(0.1 mM, 0.05 mCi/ml) with 25 mMmitoxantrone or 500 mMquinidine for
inhibition studies. The intestinal epithelial segments were incubated for
5minutes at 37°C, the buffer from both chambers was aspirated, and the
tissues were washed 10 times in ice-cold KBR buffer, digested for 10
minutes with 0.2 ml of 2NNaOH at 50°C, and neutralized with 0.2 ml of
2N HCl and 0.2 ml of KBR. The fully digested tissue solution was
analyzed by liquid scintillation spectrometry, and the rate of initial
uptake of [3H]pentamidine was determined.
For the mouse studies, male C57BL/6 mice (The Jackson Labo-
ratories, Bar Harbor, ME) were housed according to approved Asso-
ciation for Assessment and Accreditation of Laboratory Animal Care
(AAALAC) and the University of North Carolina at Chapel Hill
Institutional Animal Care and Use Committee (IACUC) require-
ments and protocols and in compliance with the Animal Welfare Act
public laws. Mice were fasted overnight and then anesthetized with
an i.p. injection of urethane (1.2–1.5 g/kg). A 10-cm segment of
jejunum was dissected and flushed with 10 ml ice-cold KBR with 50%
complete EDTA-free protease inhibitors. The intestinal segment was
separated into 2-cm segments and mounted in a diffusion chamber,
and the [3H]pentamidine uptake in mouse intestinal tissue was
determined as described with the exception of a mOct1 specific
inhibitor, desipramine (10 mM), being used instead of mitoxantrone
(Costales et al., 2011). Quinidine (500 mM) was used as a pan
inhibitor.
Western Blot Analysis
The specificity of the primary rabbit anti-human OCT1 antibody
was confirmed by Western blot analysis. Chinese hamster ovary
(CHO) cells were cultured as described previously elsewhere (Ming
et al., 2009). CHO cells singly transfected with human OCT1-3 or
mouse mOct1-3, parental CHO K1 cells, Caco-2 cells (including wild-
type and OCT1 knockdown Caco-2 cells), human liver, mouse liver,
and mouse kidney specimens were lysed and homogenized in a
radioimmunoprecipitation assay buffer system according to the manu-
facturer’s protocol (Santa Cruz Biotechnology). The homogenized lysates
were centrifuged at 14,000g for 15 minutes at 4°C. The pellets were
discarded, and protein content in the supernatants was measured with
a bicinchoninic acid protein assay kit (Pierce, Rockford, IL) with bovine
serum albumin as a standard.
Proteins were denatured with Nupage loading buffer and reducing
agent, and heated at 70°C for 10 minutes. After being cooled to room
temperature, the protein samples (20 mg each lane) were loaded to 4–
12% (gradient) Bis-Tris gel, and separated by electrophoresis (200 V,
160mA for 1 hour) and transferred to nitrocellulose membranes (30 V,
160 mA for 1 hour). The membranes were probed with rabbit anti-
human OCT1 antibody followed by goat anti-rabbit IgG-horseradish
peroxidase secondary antibody. Positive protein bands were detected
with SuperSignal West Dura Extended Duration Substrate Kit
(Thermo Scientific) and imaged by the Versa Doc Imaging System
Model 1000 (Bio-Rad Laboratories, Hercules, CA). After imaging, the
membrane was stripped, washed, and analyzed for glyceraldehyde-3-
phosphate dehydrogenase.
Laser Scanning Confocal Microscopy
Caco-2 Cell Monolayers. Caco-2 cells grown on Transwells for
21–28 days were washed 3 times in phosphate-buffered saline (PBS),
frozen in Tissue-Tek Cryo-OCT Compound (Sakura Fineteck, Tor-
rance, CA), cut longitudinally into 5 mM thick sections, and fixed on
glass slides with the AP side of the Caco-2 cells facing up so that the
polarity of the cells could be readily identified. The sections were rinsed
with PBS and permeabilized for 10 minutes in 0.5% Triton X-100 in
PBS. The sections were blocked for 30minutes with PBS containing 5%
NGS followed by incubation with rabbit anti-human OCT1 primary
antibodies (1:75 dilution) or rabbit anti-human P-gp primary anti-
bodies (1:100 dilution) for 1 hour at room temperature. The slides were
rinsed 3 times in PBS and then incubated with a secondary antibody
(Alexa Fluor 568-conjugated goat anti-rabbit IgG for OCT1 or Alexa
Fluor 488-conjugated goat anti-rabbit IgG for P-gp) for 1 hour at room
temperature in the dark. After washing the slides 3 times in PBS,
mounting medium with DAPI was applied for nuclear staining, and
confocal images were obtained with a Leica SP2 AOBS laser scanning
confocal microscope (Leica Microsystems, Wetzlar, Germany).
To visualize the localization of a BL biomarker against which AP
localization of OCT1 can be compared, rabbit anti-Na1/K1 ATPase
primary antibody (1:100 dilution) was used to detect Na1/K1 ATPase
which is known to be confined to the BLmembrane of Caco-2 cells and
enterocytes. Alexa Fluor 568-conjugated goat anti-rabbit IgG was
used as a secondary antibody.
Human andMouse Intestinal Tissue. Slides containing paraffin-
fixed human or mouse jejunum tissue sections were deparaffinized
in xylene 3 times for 5 minutes, rehydrated in serial ethanol dilutions
(2 times for 3 minutes in 100% ethanol, 1 minute in 95%, 1 minute in
80%, then rinsed in distilled water), and transferred to PBS. Slides were
incubated in citrate buffer (10 mM citric acid, 0.05% Tween 20, pH 6.0)
at 95–100°C for 30 minutes for antigen retrieval, and cooled down to
room temperature.
The tissues were permeabilized with 0.5% Triton X-100 in PBS for
10 minutes, transferred back to PBS and blocked for 30 minutes with
PBS containing 5% NGS, then incubated with rabbit anti-human
OCT1 primary antibodies (1:75 dilution), rabbit anti-human P-gp
primary antibodies (1:100 dilution), or rabbit anti-Na1/K1 ATPase
primary antibody (1:100 dilution) for 1 hour at room temperature. The
tissues were rinsed 3 times in PBS and then incubated with the
secondary antibody (Alexa Fluor 568-conjugated goat anti-rabbit IgG
for OCT1 and Na1/K1 ATPase; or Alexa Fluor 488-conjugated goat
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anti-rabbit IgG for P-gp) for 1 hour at room temperature in the dark.
After the tissues were washed three times in PBS, the mounting
medium containing DAPI was applied, and confocal images were
obtained with a Leica SP2 AOBS laser scanning confocal microscope.
To demonstrate colocalization of OCT1 (mOct1) with villin in Caco-
2 cells and intestinal tissues, rabbit anti-human OCT1 and goat anti-
human villin primary antibodies were applied together for 1 hour at
room temperature, washed, and Alexa Fluor 568-goat anti-rabbit IgG
and Alexa Fluor-488 donkey anti-goat IgG secondary antibodies were
applied together to the cells or tissue slides. After washing, mounting
medium with DAPI was applied, and confocal images were obtained
with a Leica SP2 AOBS laser scanning confocal microscope.
Results
Functional Evidence for the Absence of Cation-
Selective BL Transporters in Caco-2 Cell Monolayers
and Enterocytes. TEA, a substrate for cation-selective trans-
porters, was not taken up across the BL membrane of Caco-2
cell monolayers via a transporter-mediated process. This was
evidenced by the result: the BL uptake of [14C]TEA was not
inhibited by unlabeled TEA at a 100-fold greater concentra-
tion or by the potent inhibitor of organic cation transporters
quinidine (Fig. 1A). In contrast, unlabeled TEA and quinidine
inhibited the uptake of [14C]TEA across the AP membrane of
Caco-2 cell monolayers by approximately 50 and 90%, re-
spectively (Fig. 1A).
These results suggest that the BL membrane of Caco-2 cell
monolayers does not express cation-selective transporters that
can facilitate the transport of TEA, whereas one or more cation-
selective transporters in theAPmembranemediate TEAuptake.
Similarly, our results demonstrate that uptake of pentamidine,
a selective substrate for OCT1 over OCT2 or OCT3 (Ming et al.,
2009), was notmediated by OCT1 at the BLmembrane of Caco-2
cell monolayers because the uptake was not inhibited by the
selective OCT1 inhibitor mitoxantrone (Koepsell et al., 2007;
Han et al., 2012) or the cationic transporter pan inhibitor
quinidine. In contrast, ∼50% of pentamidine uptake across the
AP membrane was inhibited by mitoxantrone or quinidine (Fig.
1B). Collectively, these results provide strong evidence that the
BL membrane of Caco-2 cell monolayers is devoid of OCT
transporters, and that these transporters, including OCT1, are
functional in the AP membrane.
Similar results were obtained with human intestinal epi-
thelium and mouse intestinal tissue, where uptake of pent-
amidine across the BL membrane was not inhibited by the
selective inhibitor of OCT1 (mitoxantrone) and mOct1 [de-
sipramine 10 mM; IC50 values for mOct1 5 1.2 6 1.1 mM,
mOct2 5 11 6 1.3 mM, mOct3 5 84 6 1.1 mM (unpublished
data)] (Costales et al., 2011), or the pan inhibitor quinidine;
but these inhibitors inhibited pentamidine uptake across the
AP membrane by ∼50% (Fig. 1, C and D). These data imply
that functionally active OCT1 localizes in the AP membrane
of Caco-2 cell monolayers and human and mouse intestinal
tissues, and is absent in the BL membrane.
AP and BL Uptake of Pentamidine in OCT1 Knock-
down Caco-2 Clones. To confirm results from the chemical
inhibition studies that provided evidence for functional
localization of OCT1 in Caco-2 cells monolayers, we evaluated
pentamidine uptake in Caco-2 cell monolayers in which OCT1
expression was downregulated by OCT1-specific shRNA.
Three clones in which OCT1 expression was reduced by 70%
ormore were selected for experimentation (Fig. 2A). Uptake of
pentamidine across the AP membrane was decreased by 50%
Fig. 1. AP and not BL uptake of TEA
and pentamidine is reduced by OCT1
inhibitors in Caco-2 cell monolayers,
human intestinal epithelium, andmouse
intestinal tissue. (A) Initial uptake (10
minutes) of [14C]TEA (5mM, 0.05mCi/ml)
across the AP and BL membranes of
Caco-2 cellswasmeasured in the absence
(open bars) or presence of unlabeled TEA
(500 mM) (hatched bars) or quinidine
(500 mM) (solid bars). Initial uptake (5
minutes) of [3H]pentamidine (0.1 mM,
0.05 mCi/ml) in Caco-2 cell monolayers
(B), human intestinal epithelium (C),
and mouse intestinal tissue (D) across
AP and BL membrane in the absence
(open bars) and presence of mitoxan-
trone (25 mM) for OCT1 or desipra-
mine (10 mM) for mOct1 (hatched
bars), or quinidine (500 mM) (solid
bars). Data represent the mean 6 S.D.
(n = 3). *P, 0.05; **P, 0.01, compared
with control.
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in OCT1-knockdown clones compared with control Caco-2 cell
monolayers (Fig. 2B). Similar to the results from the chemical
inhibition studies, the BL uptake of pentamidine in the OCT1-
knockdown clones was not significantly different from that of
control cells (Fig. 2C). Data from chemical inhibition and
OCT1-knockdown studies provided definitive evidence that
OCT1 in Caco-2 cell monolayers is not localized in the BL
membrane but is present in the AP membrane.
Specificity of the Rabbit Anti-Human OCT1 Antibody
for OCT1 and mOct1. To use the rabbit anti-human OCT1
antibody to assess the cellular localization of OCT1 and
mOct1, it was important to demonstrate by Western blot
analysis that the antibody detects OCT1 and does not cross-
react with OCT2 or OCT3, but does cross-react with mOct1.
Protein extracts from CHO cells that are singly transfected
with OCT (mOct) transporters (OCT1-CHO, OCT2-CHO,
OCT3-CHO, mOct1-CHO, mOct2-CHO, mOct3-CHO), paren-
tal CHO K1 cells, wild-type Caco-2 cells, OCT1 knockdown
Caco-2 cells (clone 3-27), human liver, mouse liver, and
mouse kidney were probed with the rabbit anti-human OCT1
antibody. The antibody specifically bound to a ∼60 kDa
protein, which is the expected size of OCT1 (mOct1), in the
protein extracts of the OCT1-CHO cells, mOct1-CHO cells,
wild-type Caco-2 cells, and human and mouse liver homoge-
nates (positive controls). In contrast, the antibody either did
not yield a band or yielded a faint band with the protein
extracts of the OCT2-3 CHO cells, mOct2-3 CHO cells, CHO
K1 cells, OCT1 knockdown Caco-2 cells, and mouse kidney
(negative control) (Fig. 3). These results confirm that the
rabbit anti-human OCT1 antibody detects OCT1 and mOct1
without producing a false-positive signal with OCT2-3 (mOct2-3).
Immunolocalization of OCT1 by Confocal Imaging in
Caco-2 Cells and Human and Mouse Intestinal Tissues.
Immunostaining and confocal microscopy studies in Caco-2
cell monolayers revealed that OCT1 is localized in the AP
membrane (Fig. 4A). The efflux transporter P-gp, which is
known to be exclusively localized in the AP membrane of
Caco-2 cells, was found to be localized in the same membrane
as OCT1 (Fig. 4B), thus confirming the AP expression of
OCT1. Further, these studies confirmed that OCT1 is not
expressed in the membrane where the BL membrane marker
Na1/K1 ATPase was immunostained (Fig. 4C). Thus, the
distinct difference in the polarized localization of OCT1 and
Na1/K1 ATPase and the unmistakable overlap in the mem-
brane localization of OCT1 and P-gp unequivocally confirm
that OCT1 is localized in the AP membrane of Caco-2 cells.
Similarly, OCT1 (mOct1) was found to be localized in the
same membrane as P-gp in human (Fig. 4, D–F) and mouse
enterocytes (Fig. 4, G–I), confirming AP localization of OCT1
(mOct1) in these tissues.
Finally, because colocalization of OCT1 (mOct1) with P-gp
in the same cell/tissue preparation did not produce a good
signal due to lack of appropriate secondary antibodies,
colocalization of OCT (mOct1) with villin, another apically
localized protein, was investigated by immunostaining and
confocal microscopy (Fig. 5). When images of antibody-labeled
OCT1 (mOct1) (red fluorescence) and villin (green fluorescence)
Fig. 2. AP and not BL uptake of pentamidine is reduced in OCT1
knockdown Caco-2 clones compared with wild-type Caco-2 cells. (A) OCT1
mRNA expression in control Caco-2 cells (open bar) and OCT1 knockdown
Caco-2 clones 1-43, 3-21, and 3-27 (hatched bars) (n = 1). (B) AP and (C) BL
uptake of [3H]pentamidine (0.1 mM, 0.05 mCi/ml) (5 minutes) in the
absence (open bars) and presence (solid bars) of mitoxantrone (25 mM) in
control Caco-2 cells, and in OCT1 knockdown Caco-2 clones 1-43, 3-21, and
3-27 (hatched bars). In B and C, data represent the mean 6 S.D. (n = 3).
**P , 0.01 compared with control.
Fig. 3. Western blot analysis shows the specificity of rabbit anti-human OCT1 antibody for OCT1 and cross-reactivity with mOct1. Lanes 1–12: lane 1,
OCT1-CHO; lane 2, OCT2-CHO; lane 3, OCT3-CHO; lane 4, mOct1-CHO; lane 5, mOct2-CHO; lane 6, mOct3-CHO; lane 7, parental CHOK1 cells; lane 8,
wild-type Caco-2 cells; lane 9, OCT1-knockdown Caco-2 cells; lane 10, human liver homogenate; lane 11, mouse liver homogenate; lane 12, mouse kidney
homogenate. Anti-human OCT1 antibody is specifically bound to a protein with an apparent molecular mass of ∼60 kDa as shown. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used as the loading control. Gene expression studies showed high expression of mOct1 in the mouse liver tissue
and low expression in the mouse kidney tissue (data in Supplemental Fig. 2; associated Supplemental Materials and Methods).
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were merged, colocalization of these two proteins in Caco-2 cell
as well as in human andmouse intestinal tissues was evidenced
by a yellow color, thus unequivocally confirming the AP lo-
calization of OCT1 (mOct1).
Discussion
The results presented here contradict several reports that
concluded that OCT1 (mOct1) is localized in the BL mem-
brane of Caco-2 cell monolayers and enterocytes. The first
suggestion that OCT1 (mOct1) is localized basolaterally
in the intestinal epithelium came from studies by Jonker
et al. (2001) based on their observation that approximately
twice the amount of [14C]TEA was found in the intestinal
content of gall bladder–cannulated wild-type mice compared
with mOct12/2 mice at 60 minutes after intravenous in-
jection. However, it should be noted that the amount of TEA
found in the intestinal content represented only 0.7 and 1.3%
of the total excretion in mOct12/2 and wild-type mice, re-
spectively, and that distribution of TEA in the liver was
reduced by 4-fold in mOct12/2 mice compared with the wild-
type mice. Further, the intestinal excretion of 1-methyl-
4-phenylpyridinium, another mOct1 substrate, was not
significantly different in mOct12/2 and wild-type mice. This
was consistent with the findings of Bleasby et al. (2000) that
showed that in Caco-2 cells OCT1 does not play a role in the
BL uptake of 1-methyl-4-phenylpyridinium. Thus, the con-
clusion by Jonker et al. (2001) that mOct1 is basolaterally
localized in the intestinal epithelium based on their results
was tenuous.
Later, Wang et al. (2002) showed that the amount of
metformin associated with the duodenum, jejunum, and
ileum was 3- to 7-fold higher in wild-type mice than in
mOct12/2 mice. The authors interpreted these results to be
suggestive of the presence of mOct1 in the BL membrane of
the intestinal epithelium because this membrane faces the
serosal blood capillaries. However, they appropriately in-
dicated that this hypothesis should be tested with further
experiments.
Using functional studies of sulpiride uptake, Watanabe
et al. (2002a,b) suggested that OCT1 is localized at the BL
membrane of Caco-2 cells. Subsequently, in Caco-2 cell
monolayers that are widely used to study intestinal drug
absorption and that exhibit low but detectable levels of OCT1
mRNA (Muller et al., 2005; Englund et al., 2006; Seithel et al.,
2006), BL localization of OCT1 was reported by Muller et al.
(2005) based on immunostaining and confocal microscopy
studies. They also reported BL localization of OCT1 in human
intestinal tissue. However, the immunohistochemical images
in this report show weak signals and widespread cellular
distribution of OCT1, including the cytoplasm and entire cell
membrane. This is likely due to the use in this study of a rat
Oct1 antibody that was not sufficiently selective for the
human OCT1 transporter. Taken together, this body of work
has not provided conclusive evidence for BL localization of
OCT1 (mOct1) in the intestinal epithelium, and it needs to be
reinterpreted in light of our results.
Our results are highly significant because all the experi-
mental observations since 2001 involving the intestinal
absorption or secretion of cationic compounds have been
interpreted based on the previously-mentioned studies that
reported BL localization of OCT1 (mOct1). Our results
warrant that the literature since 2001 on intestinal absorp-
tion and disposition of cationic drugs be re-evaluated. Our
findings could impact not only the results involving the
intestinal absorption of a single drug but also reports on drug-
drug interactions of coadministered drugs that implicate
intestinal OCT1 (mOct1). It is important to note that several
reviews and the US Food and Drug Administration (FDA)
guidance for the industry (CDER, 2012; http://www.fda.gov/
downloads/Drugs/GuidanceComplianceRegulatoryInformation/
Guidances/UCM292362.pdf) state that OCT1 is localized in
Fig. 4. Immunocytochemical localization of OCT1 (mOct1) in Caco-2 cell
monolayers and in human and mouse intestinal tissues. (A) OCT1, (B)
P-gp, and (C) Na+/K+ ATPase localization in Caco-2 cell monolayers. The
orientation of the monolayers shows the AP side facing up and the basal
side facing down. (D) OCT1, (E) P-gp, and (F) Na+/K+ ATPase localization
in human intestinal tissues. (G) mOct1, (H) P-gp, and (I) Na+/K+ ATPase
localization in mouse intestinal tissues. Blue fluorescence represents
nuclear staining with DAPI. Larger amplifications of the boxed area in
D–I were shown as D9–I9, respectively.
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the BL membrane of the enterocytes. The FDA guidance
impacts numerous drug development decisions involving
compounds that are likely or known substrates/inhibitors of
OCT1. Clearly, a re-evaluation and revision of the FDA guid-
ance is warranted.
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